Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

NCT04184921 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
216
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University